The Coordination and Admissions Committee of the Mercado Alternativo Bursátil (MAB) has submitted to the Board of Directors a favourable report on Atrys Health,stating that the company is eligible for admission to the market’s Growth Companies segment following a thorough review of all the information presented by the company.
Prior to its listing on MAB, which requires the final approval of MAB’s Board of Directors, the company will carry out a public share offering.
Atrys Health’s Informative Document is available on www.bolsasymercados.es/mab, where all the information about the company and its activities can be found.
NORGESTION is acting as Registered Adviser and Banco Sabadell as Liquidity Provider.
Atrys Health aims to offer its patients personalised therapies as well as the development of new therapeutical treatments and diagnosis tools. It has operations in America and Europe, with clients in 7 countries, namely the US, Switzerland, United Kingdom, Germany, Denmark, Portugal and Spain.
The Market Status informs through quick and easy-to-read notices on incidents affecting the Equity, Derivatives and Fixed Income markets as well as Indices and financial systems operated by BME.
If an issue occurs, the message "TRADING" will change to "MARKET ISSUE" to reflect that a market event has occurred. By clicking on the Issue of the published alert it will be possible to access the information and intraday updates associated with this incident, which will be published immediately.
Note: BME will use its discretion to assign the severity of an incident